1,734 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Buy
Article Searches
What's in the Cards for Skyworks (SWKS) in Q1 Earnings? http://www.zacks.com/stock/news/351009/whats-in-the-cards-for-skyworks-swks-in-q1-earnings?cid=CS-ZC-FT-351009 Jan 31, 2019 - Skyworks (SWKS) is benefiting from its portfolio strength, particularly in the 5G applications and IoT market.
IPO Update: Alector Readies Terms For $176 Million IPO https://seekingalpha.com/article/4236741-ipo-update-alector-readies-terms-176-million-ipo?source=feed_tag_ipo_analysis Jan 30, 2019 -
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate http://www.zacks.com/stock/news/350873/roche-halts-two-late-stage-studies-on-alzheimers-candidate?cid=CS-ZC-FT-350873 Jan 30, 2019 - Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Why Merck (MRK) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/350358/why-merck-mrk-could-beat-earnings-estimates-again?cid=CS-ZC-FT-350358 Jan 29, 2019 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update https://seekingalpha.com/article/4236060-tracking-ken-fishers-fisher-asset-management-portfolio-q4-2018-update?source=feed_all_articles Jan 28, 2019 - Fisher’s 13F portfolio value decreased from $82.37B to $73.22B in Q4 2018.Visa Inc., Amazon.com, Apple Inc., Microsoft, and Pfizer are the largest five individual stock positions.Fisher has substantia
Gossamer Bio IPO: A Lot Of Cash And At Phase 2 Of Development https://seekingalpha.com/article/4235956-gossamer-bio-ipo-lot-cash-phase-2-development?source=feed_tag_ipo_analysis Jan 28, 2019 - Gossamer Bio is a clinical-stage biopharmaceutical company testing treatments in disease areas of immunology, inflammation, and oncology.The most appealing of this name is that it has diverse research
BMS Reports Q4: Analysis Of Its Stock And Of Celgene https://seekingalpha.com/article/4235849-bms-reports-q4-analysis-stock-celgene?source=feed_sector_healthcare Jan 27, 2019 - Bristol-Myers Squibb reported a solid Q4 and pretty good guidance for 2019, but revenue growth is slowing.In that context and given poor new drug development the last few years, it makes sense for BMS
Tech Giants Step To The Plate (Stocks To Watch Podcast) https://seekingalpha.com/article/4235804-tech-giants-step-plate-stocks-watch-podcast?source=feed_all_articles Jan 27, 2019 -
Stocks To Watch: Tech Giants Step To The Plate https://seekingalpha.com/article/4235782-stocks-watch-tech-giants-step-plate?source=feed Jan 26, 2019 -
MRK: BMO Capital Markets cuts to Market Perform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190125123740 Jan 25, 2019 - BMO Capital Markets issues rating change for MRK

Pages: 1234567891011...174

<<<Page 6>